Dyne Therapeutics, Inc. $DYN Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lessened its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 5.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,322 shares of the company’s stock after selling 2,228 shares during the quarter. Wellington Management Group LLP’s holdings in Dyne Therapeutics were worth $380,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of DYN. Jefferies Financial Group Inc. acquired a new position in shares of Dyne Therapeutics during the fourth quarter worth about $42,408,000. Point72 Asset Management L.P. lifted its stake in shares of Dyne Therapeutics by 802.3% during the fourth quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company’s stock worth $21,785,000 after purchasing an additional 822,201 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Dyne Therapeutics by 10.5% during the first quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company’s stock worth $77,470,000 after purchasing an additional 702,418 shares in the last quarter. Braidwell LP acquired a new position in shares of Dyne Therapeutics during the fourth quarter worth about $16,049,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Dyne Therapeutics by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock worth $173,808,000 after purchasing an additional 566,146 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Down 1.9%

Shares of Dyne Therapeutics stock opened at $13.49 on Tuesday. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.92 billion, a P/E ratio of -3.49 and a beta of 1.10. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $46.26. The business has a 50-day moving average price of $10.52 and a 200 day moving average price of $11.13.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.02. On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on DYN shares. Guggenheim restated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Sanford C. Bernstein started coverage on Dyne Therapeutics in a research note on Tuesday, June 24th. They issued a “market perform” rating and a $13.00 price target on the stock. Raymond James Financial upgraded Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $31.00 to $35.00 in a research note on Monday, August 25th. Robert W. Baird cut their price target on Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 18th. Finally, Evercore ISI reiterated an “outperform” rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $34.07.

Insiders Place Their Bets

In other news, CEO John Cox acquired 100,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was purchased at an average cost of $9.11 per share, with a total value of $911,000.00. Following the completion of the acquisition, the chief executive officer directly owned 242,179 shares in the company, valued at $2,206,250.69. This represents a 70.33% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 20.77% of the stock is currently owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.